Enteropeptidase inhibitor SCO-792 effectively prevents kidney function decline and fibrosis in a rat model of chronic kidney disease
Inhibiting enteropeptidase suppresses food intake and ameliorates obesity and diabetes in mice. The study found a decline in glomerular filtration rate (GFR) for five weeks with SCO-792. It also improved glomerulosclerosis and kidney fibrosis. It did not affect the renal plasma flow, suggesting its effect on GFR was mediated by an improved filtration fraction.SCO-792-mediated inhibition of enteropeptidase prevented GFR decline, albuminuria, and kidney fibrosis; hence, it may have therapeutic pot
